-
1
-
-
84933277181
-
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
-
Llovet, JM, Villanueva, A, Lachenmayer, A, Finn, RS, Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 12 (2015), 408–424.
-
(2015)
Nat Rev Clin Oncol
, vol.12
, pp. 408-424
-
-
Llovet, J.M.1
Villanueva, A.2
Lachenmayer, A.3
Finn, R.S.4
-
2
-
-
85041118637
-
The immunology of hepatocellular carcinoma
-
Ringelhan, M, Pfister, D, O'Connor, T, Pikarsky, E, Heikenwalder, M, The immunology of hepatocellular carcinoma. Nat Immunol 19 (2018), 222–232.
-
(2018)
Nat Immunol
, vol.19
, pp. 222-232
-
-
Ringelhan, M.1
Pfister, D.2
O'Connor, T.3
Pikarsky, E.4
Heikenwalder, M.5
-
3
-
-
57749189578
-
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
-
Cheng, AL, Kang, YK, Chen, Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009), 25–34.
-
(2009)
Lancet Oncol
, vol.10
, pp. 25-34
-
-
Cheng, A.L.1
Kang, Y.K.2
Chen, Z.3
-
4
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet, JM, Ricci, S, Mazzaferro, V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
-
5
-
-
85042855944
-
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
-
Kudo, M, Finn, RS, Qin, S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391 (2018), 1163–1173.
-
(2018)
Lancet
, vol.391
, pp. 1163-1173
-
-
Kudo, M.1
Finn, R.S.2
Qin, S.3
-
6
-
-
85038641656
-
Systemic therapy for hepatocellular carcinoma: 2017 update
-
Kudo, M, Systemic therapy for hepatocellular carcinoma: 2017 update. Oncology 93:suppl 1 (2017), 135–146.
-
(2017)
Oncology
, vol.93
, pp. 135-146
-
-
Kudo, M.1
-
7
-
-
85007560261
-
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
-
Bruix, J, Qin, S, Merle, P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389 (2017), 56–66.
-
(2017)
Lancet
, vol.389
, pp. 56-66
-
-
Bruix, J.1
Qin, S.2
Merle, P.3
-
8
-
-
85042883711
-
Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase III CELESTIAL trial
-
Abou-Alfa, GK, Meyer, T, Cheng, AL, et al. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase III CELESTIAL trial. Proc Am Soc Clin Oncol, 36(suppl 4), 2018, 207.
-
(2018)
Proc Am Soc Clin Oncol
, vol.36
, pp. 207
-
-
Abou-Alfa, G.K.1
Meyer, T.2
Cheng, A.L.3
-
9
-
-
85049271441
-
Lilly announces CYRAMZA (ramucirumab) phase 3 REACH-2 Study in second-line hepatocellular carcinoma patients met overall survival endpoint
-
(Accessed 25 April 2018)
-
Eli Lilly and Company. Lilly announces CYRAMZA (ramucirumab) phase 3 REACH-2 Study in second-line hepatocellular carcinoma patients met overall survival endpoint. https://investor.lilly.com/news-releases/news-release-details/lilly-announces-cyramzar-ramucirumab-phase-3-reach-2-study, April 4, 2018. (Accessed 25 April 2018)
-
(2018)
-
-
-
10
-
-
84949112760
-
Immunological landscape and immunotherapy of hepatocellular carcinoma
-
Prieto, J, Melero, I, Sangro, B, Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 12 (2015), 681–700.
-
(2015)
Nat Rev Gastroenterol Hepatol
, vol.12
, pp. 681-700
-
-
Prieto, J.1
Melero, I.2
Sangro, B.3
-
11
-
-
57349090407
-
Gene expression in fixed tissues and outcome in hepatocellular carcinoma
-
Hoshida, Y, Villanueva, A, Kobayashi, M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359 (2008), 1995–2004.
-
(2008)
N Engl J Med
, vol.359
, pp. 1995-2004
-
-
Hoshida, Y.1
Villanueva, A.2
Kobayashi, M.3
-
12
-
-
61549122071
-
Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma
-
Gao, Q, Wang, XY, Qiu, SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15 (2009), 971–979.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 971-979
-
-
Gao, Q.1
Wang, X.Y.2
Qiu, S.J.3
-
13
-
-
78650621479
-
PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
-
Shi, F, Shi, M, Zeng, Z, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 128 (2011), 887–896.
-
(2011)
Int J Cancer
, vol.128
, pp. 887-896
-
-
Shi, F.1
Shi, M.2
Zeng, Z.3
-
14
-
-
85020894317
-
Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing
-
Zheng, C, Zheng, L, Yoo, JK, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 169 (2017), 1342–1356.
-
(2017)
Cell
, vol.169
, pp. 1342-1356
-
-
Zheng, C.1
Zheng, L.2
Yoo, J.K.3
-
15
-
-
85018660134
-
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
-
El-Khoueiry, AB, Sangro, B, Yau, T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389 (2017), 2492–2502.
-
(2017)
Lancet
, vol.389
, pp. 2492-2502
-
-
El-Khoueiry, A.B.1
Sangro, B.2
Yau, T.3
-
16
-
-
85049266504
-
FDA approves nivolumab for hepatocellular carcinoma
-
(Accessed 28 February 2018)
-
OncLive. FDA approves nivolumab for hepatocellular carcinoma. http://www.onclive.com/web-exclusives/fda-approves-nivolumab-for-hepatocellular-carcinoma, Sept 22, 2017. (Accessed 28 February 2018)
-
(2017)
-
-
-
17
-
-
85032439821
-
Keytruda (pembrolizumab) prescribing information
-
(Accessed 17 May 2018)
-
Merck Sharp & Dohme. Keytruda (pembrolizumab) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s015lbl.pdf, March, 2017. (Accessed 17 May 2018)
-
(2017)
-
-
-
18
-
-
84928774156
-
The future of immune checkpoint therapy
-
Sharma, P, Allison, JP, The future of immune checkpoint therapy. Science 348 (2015), 56–61.
-
(2015)
Science
, vol.348
, pp. 56-61
-
-
Sharma, P.1
Allison, J.P.2
-
19
-
-
57849117384
-
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
-
Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
-
(2009)
Eur J Cancer
, vol.45
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
-
20
-
-
84881128653
-
Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements
-
Nishino, M, Giobbie-Hurder, A, Gargano, M, et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 19 (2013), 3936–3943.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 3936-3943
-
-
Nishino, M.1
Giobbie-Hurder, A.2
Gargano, M.3
-
21
-
-
84992573817
-
Development of a companion diagnostic for pembrolizumab in non-small cell lung cancer using immunohistochemistry for programmed death ligand-1
-
Dolled-Filhart, M, Roach, C, Toland, G, et al. Development of a companion diagnostic for pembrolizumab in non-small cell lung cancer using immunohistochemistry for programmed death ligand-1. Arch Pathol Lab Med 140 (2016), 1243–1249.
-
(2016)
Arch Pathol Lab Med
, vol.140
, pp. 1243-1249
-
-
Dolled-Filhart, M.1
Roach, C.2
Toland, G.3
-
22
-
-
85049290140
-
-
Clinical utility of the combined positive score for programmed death ligand 1 expression and the approval of pembrolizumab in gastric cancer. Arch Pathol Lab Med (in press).
-
Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death ligand 1 expression and the approval of pembrolizumab in gastric cancer. Arch Pathol Lab Med (in press).
-
-
-
Kulangara, K.1
Zhang, N.2
Corigliano, E.3
-
23
-
-
77349102071
-
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma
-
Lencioni, R, Llovet, JM, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30 (2010), 52–60.
-
(2010)
Semin Liver Dis
, vol.30
, pp. 52-60
-
-
Lencioni, R.1
Llovet, J.M.2
-
24
-
-
0001072895
-
The use of confidence or fiducial limits illustrated in the case of binomial
-
Clopper, CJ, Pearson, ES, The use of confidence or fiducial limits illustrated in the case of binomial. Biometrika 26 (1934), 404–413.
-
(1934)
Biometrika
, vol.26
, pp. 404-413
-
-
Clopper, C.J.1
Pearson, E.S.2
-
25
-
-
84879141840
-
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
-
Sangro, B, Gomez-Martin, C, de la Mata, M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59 (2013), 81–88.
-
(2013)
J Hepatol
, vol.59
, pp. 81-88
-
-
Sangro, B.1
Gomez-Martin, C.2
de la Mata, M.3
-
26
-
-
85039166557
-
Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses
-
Kelley, RK, Abou-Alfa, GK, Bendel, JC, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. Proc Am Soc Clin Oncol, 35(suppl 15), 2017, 4073.
-
(2017)
Proc Am Soc Clin Oncol
, vol.35
, pp. 4073
-
-
Kelley, R.K.1
Abou-Alfa, G.K.2
Bendel, J.C.3
-
27
-
-
85020908157
-
Opdivo (nivolumab) prescribing information
-
(Accessed 17 May 2018)
-
Bristol-Meyers Squibb. Opdivo (nivolumab) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125554s019lbl.pdf, May, 2016. (Accessed 17 May 2018)
-
(2016)
-
-
-
28
-
-
84932628341
-
PD-1 blockade in tumors with mismatch-repair deficiency
-
Le, DT, Uram, JN, Wang, H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
-
(2015)
N Engl J Med
, vol.372
, pp. 2509-2520
-
-
Le, D.T.1
Uram, J.N.2
Wang, H.3
-
29
-
-
84994802263
-
Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer
-
Reck, M, Rodríguez-Abreu, D, Robinson, AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375 (2016), 1823–1833.
-
(2016)
N Engl J Med
, vol.375
, pp. 1823-1833
-
-
Reck, M.1
Rodríguez-Abreu, D.2
Robinson, A.G.3
-
30
-
-
85042622600
-
KEYNOTE-059 update: efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer
-
Wainberg, ZA, Jalal, S, Muro, K, et al. KEYNOTE-059 update: efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer. Ann Oncol, 28(suppl 5), 2017.
-
(2017)
Ann Oncol
, vol.28
-
-
Wainberg, Z.A.1
Jalal, S.2
Muro, K.3
-
31
-
-
84939227614
-
Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers
-
Carbognin, L, Pilotto, S, Milella, M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One, 10, 2015, e0130142.
-
(2015)
PLoS One
, vol.10
, pp. e0130142
-
-
Carbognin, L.1
Pilotto, S.2
Milella, M.3
-
32
-
-
84929481480
-
Pembrolizumab for the treatment of non-small-cell lung cancer
-
Garon, EB, Rizvi, NA, Hui, R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
-
(2015)
N Engl J Med
, vol.372
, pp. 2018-2028
-
-
Garon, E.B.1
Rizvi, N.A.2
Hui, R.3
-
33
-
-
85025439295
-
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
-
Overman, MJ, McDermott, R, Leach, JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18 (2017), 1182–1191.
-
(2017)
Lancet Oncol
, vol.18
, pp. 1182-1191
-
-
Overman, M.J.1
McDermott, R.2
Leach, J.L.3
|